DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

Author(s): Baden LR(1), Liu J(2), Li H(2), Johnson JA(3), Walsh SR(4), Kleinjan JA(5), Engelson BA(5), Peter L(2), Abbink P(2), Milner DA Jr(3), Golden KL(3), Viani KL(3), Stachler MD(3), Chen BJ(3), Pau MG(6), Weijtens M(6), Carey BR(7), Miller CA(7), Swann EM(8), Wolff M(9), Loblein H(9), Seaman MS(10), Dolin R(1), Barouch DH(10).

Affiliation(s): Author information: (1)Brigham and Women's Hospital Beth Israel Deaconess Medical Center Harvard Medical School Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston. (2)Beth Israel Deaconess Medical Center Harvard Medical School. (3)Brigham and Women's Hospital Harvard Medical School. (4)Brigham and Women's Hospital Beth Israel Deaconess Medical Center Harvard Medical School. (5)Brigham and Women's Hospital. (6)Crucell Holland BV, Leiden, The Netherlands. (7)Beth Israel Deaconess Medical Center. (8)Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. (9)EMMES Corporation, Rockville. (10)Beth Israel Deaconess Medical Center Harvard Medical School Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston.

Publication date & source: 2015, J Infect Dis. , 211(4):518-28

BACKGROUND: Defining mucosal immune responses and inflammation to candidate human immunodeficiency virus type 1 (HIV-1) vaccines represents a current research priority for the HIV-1 vaccine field. In particular, it is unclear whether intramuscular immunization can elicit immune responses at mucosal surfaces in humans. METHODS: In this double-blind, randomized, placebo-controlled clinical trial, we evaluated systemic and mucosal immune responses to a candidate adenovirus serotype 26 (Ad26) vectored HIV-1 envelop (Env) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers. Systematic mucosal sampling with rectal Weck-Cel sponges and rectal biopsies were performed. RESULTS: Intramuscular immunization elicited both systemic and mucosal Env-specific humoral and cellular immune responses in the majority of subjects. Individuals with preexisting Ad26-specific neutralizing antibodies had vaccine-elicited immune responses comparable to those of subjects who were Ad26 seronegative. We also observed no increase in activated total or vector-specific mucosal CD4+ T lymphocytes following vaccination by either histopathology or flow cytometry. CONCLUSIONS: These data demonstrate that a single intramuscular administration of this Ad26-vectored HIV-1 Env vaccine elicited both systemic and mucosal immune responses in humans. Induction of antigen-specific humoral and cellular mucosal immunity was not accompanied by a detectable increase in mucosal inflammation. CLINICAL TRIALS REGISTRATION: NCT01103687.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017